이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

2026년 6월 18일 업데이트: Hangzhou Highlightll Pharmaceutical Co., Ltd

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

This study is a randomized, double-blind, placebo-controlled, multicenter Phase Ib/II clinical study designed to evaluate the efficacy, safety, and PK characteristics of HL-300 ointment with different concentration regimens for mild-to-moderate AD.

연구 개요

상세 설명

In the study, it is planned to enroll approximately 148-156 trial participants, divided into two cohorts. Cohort 1: a randomized, double-blind, placebo-parallel controlled study design, planning to enroll 140 trial participants, randomized in a 1:1:1:1 ratio to the study group or placebo group, with baseline disease severity (mild [vIGA-AD = 2] and moderate [vIGA-AD = 3]) set as stratification factors to ensure balanced participant status across groups. Cohort 2: an open-label, intensive sampling design, planning to enroll 8 trial participants for each dosage strength, enrolled separately, with continuous dosing for 8 days.

The study includes a screening period, a treatment period, and a follow-up period. The quality management system for this trial aims to prospectively integrate quality by design into all aspects of the trial to ensure the rights and interests, safety, and well-being of trial participants, and to guarantee the reliability of the generated data and the scientific validity of the trial results. This system strictly adheres to the principles of ICH E6(R3) and ICH E8(R1), employing a risk-based and proportionate approach.

During the trial design phase, the investigators have systematically identified the critical to quality (CtQ) factors for ensuring the quality of this trial. Given the known safety profile of JAK inhibitors (e.g., infections, hematologic abnormalities, hepatic and renal function effects, thrombosis, etc.), the CtQ factors for this trial will specifically focus on:

  • Trial participant safety: Identification, recording, assessment, and timely reporting of Adverse Events (AEs) and Serious Adverse Events (SAEs).
  • Key efficacy data: Accuracy and integrity of data collection related to the primary and secondary endpoints of the trial (e.g., vIGA-AD, EASI, BSA, WI-NRS, DLQI, SCORAD, etc.).
  • Critical processes: Strict adherence to inclusion/exclusion criteria during participant screening [e.g., exclusion of severe infections (including herpes zoster, tuberculosis, and other opportunistic infections) and active infections, hematologic toxicity (anemia, neutropenia), elevated transaminases, and high-risk thrombosis population], protocol-mandated laboratory tests (e.g., blood routine, blood biochemistry, urinalysis, coagulation function, etc.), completeness of randomization and blinding, concomitant medication management (e.g., contraindications for topical medications for AD or AD-related skin infections, systemic treatments for AD, systemic immunosuppressants or immunomodulators, other JAK inhibitors, etc.), rules for suspension/termination of dosing.

연구 유형

중재적

등록 (추정된)

156

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Zhejiang
      • Hangzhou, Zhejiang, 중국
        • 모병
        • Hangzhou First People's Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. Age ≥18 years and ≤75 years at the time of ICF signing, with no gender restriction
  2. Meeting the Hanifin & Rajka diagnostic criteria for atopic dermatitis (AD) at screening, with a history of AD ≥ 6 months before screening, and the AD condition judged by the investigator to be stable within 4 weeks prior to ICF signing,.
  3. vIGA-AD score of 2-3 at screening and baseline visits;
  4. EASI score within the range of 5-21 at screening and baseline;
  5. "Body Surface Area (BSA) affected by AD skin lesions meeting one of the following requirements at screening and baseline visits, with skin lesions suitable for topical treatment:

    • Cohort 1: BSA of 5% to 20%;
    • Cohort 2: BSA of 15% to 25%. "
  6. Women of childbearing potential and men willing to use at least one highly effective method of contraception or practice abstinence from the time of informed consent signing until 3 months after the last dose of the investigational product
  7. Those who voluntarily participate in the study and sign the informed consent form

Exclusion Criteria:

  1. "Trial participants with any of the following medical histories or abnormal conditions at screening: (1) Skin lesions or abnormalities that may affect the assessment of the investigational product application site; (2) Clinically relevant skin diseases that are contraindicated for the study or affect the assessment of the application site, including but not limited to: psoriasis, acne, skin cancer; (3) Other autoimmune diseases besides AD, such as inflammatory bowel disease, rheumatoid arthritis, where the investigator believes the disease would unfavorably impact the assessment of this study; (4) Current or history of lymphoproliferative disorders, or signs or symptoms suggestive of possible lymphoproliferative disorders, including lymphadenopathy or splenomegaly; (5) Any malignancy, or any history of malignancy within 5 years prior to screening (except for completely resected cervical carcinoma in situ or non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, or papillary thyroid carcinoma); (6) History of herpes virus infection within the past 6 months, or recurrent herpes zoster (≥2 episodes), disseminated herpes zoster, disseminated herpes simplex, or current inability to rule out herpes zoster or herpes simplex infection; (7) Systemic infection requiring hospitalization within 12 weeks prior to screening to baseline, or active bacterial, viral, fungal, parasitic, or other infections requiring anti-infective treatment within 4 weeks prior to screening to baseline; (8) Local active infection within 1 week prior to screening to baseline, such as active infected AD, or any superficial skin infection requiring oral or intravenous antibiotic, antifungal, or antiviral medication; (9) History of thrombotic events, including deep vein thrombosis and pulmonary embolism, or high-risk factors for thromboembolism (e.g., immobilization or prolonged bed rest), which is judged by the investigator's comprehensive clinical assessment to be unsuitable for participation in this study; (10) History of significant cardiovascular, neurological, respiratory, hematological, digestive, urinary, immune, or psychiatric diseases that the investigator believes may confound study results or affect drug absorption, distribution, metabolism, and excretion, or place the trial participant at undue risk; (11) History of drug abuse or substance abuse."
  2. "Trial participants who have received any of the following treatments: (1) Use of topical skin products for AD or AD-related skin infections at the study application site within 2 weeks prior to baseline, including but not limited to: topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), topical phosphodiesterase 4 (PDE-4) inhibitor ointments, topical antimicrobials, etc.; (2) Use of topical skin products containing chemically active ingredients (including but not limited to vitamin E cream, functional products containing niacinamide/urea/ceramide, excluding emollients without any chemically active ingredients) at the study application site within 1 week prior to baseline; (3) Use of systemic therapeutic drugs for AD within 4 weeks or 5 half-lives (whichever is longer) prior to baseline, including but not limited to systemic anti-infectives, PDE-4 inhibitors, and systemic traditional Chinese medicine or herbal medicines for AD; (4) Use of systemic or topical JAK inhibitors (such as ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib, delgocitinib, upadacitinib, abrocitinib, etc.) within 12 weeks prior to baseline; (5) Use of sedating antihistamines within 2 weeks prior to baseline (Stable use of non-sedating antihistamines is permitted [dose stable for 2 weeks or 5 half-lives (whichever is longer) before the first study medication]); (6) Use of systemic immunosuppressants or immunomodulators (such as oral or injectable corticosteroids, methotrexate, cyclosporine, mycophenolate mofetil, and azathioprine) within 4 weeks or 5 half-lives (whichever is longer) prior to baseline; (7) Use of biologics (such as dupilumab) within 12 weeks or 5 half-lives (whichever is longer) prior to baseline; (8) Use of strong CYP450 inhibitors or inducers within 2 weeks prior to baseline, including but not limited to: nelfinavir, ritonavir, clarithromycin, itraconazole, nevirapine, and barbiturates; (9) Vaccination with live/attenuated live vaccines within 4 weeks prior to baseline, or planning to receive vaccination during the study period; (10) Sunbathing or phototherapy (including ultraviolet therapy, photochemotherapy, etc.) with AD therapeutic effects within 4 weeks prior to baseline;"
  3. "Trial participants with any of the following laboratory and instrumental examination results:

(1) Any significant clinical and laboratory abnormalities that the investigator believes may affect trial participant safety, including but not limited to:

  1. White blood cell count (WBC) < 3×109/L, absolute neutrophil count (ANC) < 1.5×109/L, absolute lymphocyte count (ALC) < 0.8×109/L, platelet count (PLT) < 100×109/L, hemoglobin (Hb) < 100 g/L;
  2. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2× ULN, or total bilirubin (TBIL) ≥ 1.5× ULN;
  3. Blood creatinine > 1.5× ULN; (2) Confirmed or suspected active tuberculosis, incompletely cured tuberculosis, or active Mycobacterium tuberculosis infection (except for trial participants with documented treatment proving adequate therapy, who may enter this study based on the medical judgment of the investigator and/or infectious disease specialist) judged by the investigator and/or infectious disease specialist (combining medical history, symptoms, signs, laboratory tests, tuberculosis screening tests, and imaging findings); (3) QT interval corrected by Fridericia formula (QTcF) ≥500 ms in 12-ECG results at screening; (4) Hepatitis B surface antigen (HBsAg) positive; HBsAg negative but hepatitis B core antibody (HBcAb) positive and HBV-DNA above detection limit, or human immunodeficiency virus antibody (HIV) positive, or anti-hepatitis C virus (HCV) antibody positive and HCV-RNA positive, or Treponema pallidum antibody positive (excluding trial participants with negative non-specific syphilis antibody results and judged by the investigator to have a past history of syphilis infection that has been cured);" 4.Known or suspected allergy to the investigational product or excipients in the investigational product; 5.Female trial participants who are suspected or known to be pregnant, breastfeeding, or planning pregnancy during the trial period; 6.History of major surgery within 4 weeks prior to baseline or planned surgery during the study; 7.Significant blood loss, received blood transfusion, or donated blood (≥400 mL) within 3 months prior to baseline; 8.Participation in other clinical trials within 3 months prior to baseline; 9.Weekly alcohol consumption greater than 14 units within 3 months prior to screening (1 unit of alcohol ≈ 360 mL beer or 45 mL spirits with 40% alcohol content or 150 mL wine); 10.Other conditions judged by the investigator to be unsuitable for participation in the study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: 그룹 D
BID, day 7.
실험적: Group A
Group A:0.25%
Group A receives the investigational product at a concentration of 0.25%, BID,4 weeks.
Group B receives the investigational product at a concentration of 0.5%, BID,4 weeks.
Group A receives the investigational product at a concentration of 1.0%, BID,4 weeks.
실험적: Group B
Group B:0.5%
Group A receives the investigational product at a concentration of 0.25%, BID,4 weeks.
Group B receives the investigational product at a concentration of 0.5%, BID,4 weeks.
Group A receives the investigational product at a concentration of 1.0%, BID,4 weeks.
실험적: Group C
Group C:1.0%
Group A receives the investigational product at a concentration of 0.25%, BID,4 weeks.
Group B receives the investigational product at a concentration of 0.5%, BID,4 weeks.
Group A receives the investigational product at a concentration of 1.0%, BID,4 weeks.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Eczema Area and Severity Index (EASI)
기간: 4 weeks

Percentage change from baseline in Eczema Area and Severity Index (EASI) score at Week 4 (W4).

The EASI score ranges from 0 to 72, with higher scores indicating more severe AD.

4 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Eczema Area and Severity Index(EASI)
기간: at Weeks 1, 2, 3, and 6 after treatment.
Change from baseline in EASI score at Weeks 1, 2, 3, 4, and 6 after treatment. The EASI score ranges from 0 to 72, with higher scores indicating more severe AD.
at Weeks 1, 2, 3, and 6 after treatment.
EASI50(≥50% improvement from baseline in EASI score)
기간: at Weeks 1, 2, 3, 4, and 6 after treatment

Proportion of trial participants with ≥50% improvement from baseline in EASI score (EASI50) at Weeks 1, 2, 3, 4, and 6 after treatment.

The EASI score ranges from 0 to 72, with higher scores indicating more severe AD.

at Weeks 1, 2, 3, 4, and 6 after treatment
EASI75(≥75% improvement from baseline in EASI score)
기간: at Weeks 1, 2, 3, 4, and 6 after treatment

Proportion of trial participants with ≥75% improvement from baseline in EASI score (EASI75) at Weeks 1, 2, 3, 4, and 6 after treatment.

The EASI score ranges from 0 to 72, with higher scores indicating more severe AD.

at Weeks 1, 2, 3, 4, and 6 after treatment
EASI90(≥90% improvement from baseline in EASI score)
기간: at Weeks 1, 2, 3, 4, and 6 after treatment.

Proportion of trial participants with ≥90% improvement from baseline in EASI score (EASI90) at Weeks 1, 2, 3, 4, and 6 after treatment.

The EASI score ranges from 0 to 72, with higher scores indicating more severe AD.

at Weeks 1, 2, 3, 4, and 6 after treatment.
Validated Investigator Global Assessment for Atopic Dermatitis(vIGA-AD)
기간: at Weeks 1, 2, 3, 4, and 6 after treatment.

Proportion of trial participants achieving vIGA-AD score of 0 (clear) or 1 (almost clear) and ≥2-point improvement from baseline at Weeks 1, 2, 3, 4, and 6 after treatment.

The vIGA-AD scale divides disease severity into 5 grades (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), each corresponding to specific skin lesion morphological characteristics. A higher grade indicates greater severity.

at Weeks 1, 2, 3, 4, and 6 after treatment.
Validated Investigator Global Assessment for Atopic Dermatitis(vIGA-AD)
기간: at Weeks 1, 2, 3, 4, and 6 after treatment.

Proportion of trial participants achieving vIGA-AD score of 0 or 1 at Weeks 1, 2, 3, 4, and 6 after treatment.

The vIGA-AD scale divides disease severity into 5 grades (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), each corresponding to specific skin lesion morphological characteristics. A higher grade indicates greater severity.

at Weeks 1, 2, 3, 4, and 6 after treatment.
Numeric Rating Scale (NRS)
기간: at Weeks 1, 2, 3, 4, and 6 after treatment.

Change from baseline in weekly average itch Numeric Rating Scale (NRS) at Weeks 1, 2, 3, 4, and 6 after treatment.

This scale assesses the most severe itch intensity subjectively felt by the trial participant due to AD in the past 24 h. The scale rates itch intensity on 10 levels (0 means no itch, 10 means the worst itch imaginable), with integer scores.The higher the score, the greater the disease severity.

at Weeks 1, 2, 3, 4, and 6 after treatment.
Numeric Rating Scale (NRS)
기간: at Weeks 1, 2, 3, 4, and 6 after treatment

Percentage of trial participants with ≥4-point improvement from baseline in weekly average itch NRS at Weeks 1, 2, 3, 4, and 6 after treatment.

This scale assesses the most severe itch intensity subjectively felt by the trial participant due to AD in the past 24 h. The scale rates itch intensity on 10 levels (0 means no itch, 10 means the worst itch imaginable), with integer scores.The higher the score, the greater the disease severity.

at Weeks 1, 2, 3, 4, and 6 after treatment
Scoring Atopic Dermatitis(SCORAD)
기간: at Weeks 1, 2, 3, 4, and 6 after treatment.

]Change from baseline and percentage change from baseline in Scoring Atopic Dermatitis (SCORAD) at Weeks 1, 2, 3, 4, and 6 after treatment.

The SCORAD score ranging from 0 to 103 points. Based on the score, the condition is classified as mild (0-24 points), moderate (25-50 points), and severe (>50 points).

at Weeks 1, 2, 3, 4, and 6 after treatment.
Body Surface Area (BSA)
기간: at Weeks 1, 2, 3, 4, and 6 after treatment.

Change from baseline and percentage change from baseline in Body Surface Area (BSA) affected by AD at Weeks 1, 2, 3, 4, and 6 after treatment.

The BSA ranges from 0% to 100%. The larger the range, the more severe the affected area.

at Weeks 1, 2, 3, 4, and 6 after treatment.
Dermatology Life Quality Index (DLQI)
기간: at Weeks 1, 2, 3, 4, and 6 after treatment.

Change from baseline in Dermatology Life Quality Index (DLQI) score at Weeks 1, 2, 3, 4, and 6 after treatment.

DLQI contains 10 questions, with a total score ranging from 0 to 30.The higher the score, the greater the impact on quality of life.

at Weeks 1, 2, 3, 4, and 6 after treatment.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Wu Liming NA, Doctor of Medicine, First People's Hospital of Hangzhou

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 5월 26일

기본 완료 (추정된)

2027년 6월 30일

연구 완료 (추정된)

2027년 12월 31일

연구 등록 날짜

최초 제출

2026년 6월 1일

QC 기준을 충족하는 최초 제출

2026년 6월 1일

처음 게시됨 (실제)

2026년 6월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 6월 23일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 6월 18일

마지막으로 확인됨

2026년 6월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다